Vaxcyte, Inc.
PCVX
$31.16
-$0.29-0.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.37% | 24.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.48% | 15.90% | |||
| Operating Income | -11.48% | -15.90% | |||
| Income Before Tax | -2.65% | -32.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.65% | -32.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.65% | -32.93% | |||
| EBIT | -11.48% | -15.90% | |||
| EBITDA | -11.63% | -15.32% | |||
| EPS Basic | -2.28% | -21.61% | |||
| Normalized Basic EPS | -2.32% | -21.57% | |||
| EPS Diluted | -2.28% | -21.61% | |||
| Normalized Diluted EPS | -2.32% | -21.57% | |||
| Average Basic Shares Outstanding | 0.36% | 9.30% | |||
| Average Diluted Shares Outstanding | 0.36% | 9.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||